1.
Kerelakes DJ, Obenchain RL et al. Abciximab provides cost-effective survival
advantage in high-volume interventional practice. Am. Heart J. 140:603-10;
2000.
2.
Obenchain RL. Resampling and multiplicity in cost-effectiveness inference.
J. Biopharmaecutical Statistics. 9(4), 563-582, 1999.
3.
Obenchain RL et al. Bootstrap analyses of cost effectiveness in antidepressant
pharmacotherapy. PharmacoEconomics. 11(5):464-472, 1997.
4.
Briggs
AH, O’Brien BJ, and Blackhouse G. Thinking
Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty
in Cost-Effectiveness Studies. Annual Rev. Public Health.
23:377–401, 2002.